Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence and Booster Response to Tetravac-Acellulaire in Adolescents
NCT01546909Phase 4Completed
- Sponsor
- Sanofi
- Start
- Feb 2012
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Quadracel in diphtheria, Tetanus, pertussis and 1 more, sponsored by Sanofi. Primary endpoints: Proportion of subjects with an anti-diphtheria concentration ≥0.01 IU/mL at Day 0, Proportion of subjects with an anti-tetanus concentration ≥0.01 IU/mL at Day 0 and 8 more. Started Feb 2012; status: completed.
02
Drugs
Quadracel
03
Conditions
diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT01546909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01546909.